Safety data show ruxolitinib cream well tolerated in atopic dermatitis, vitiligo at 1 year
Safety data for ruxolitinib cream, a Janus kinase inhibitor, in the first year after its approval has shown that the drug is generally well tolerated for the treatment of atopic dermatitis or vitiligo, according to a postmarketing review.A postmarketing study with oral tofacitinib triggered a class warning for Janus kinase (JAK) inhibitors that treat certain inflammatory diseases. Although a